Literature DB >> 33449917

Pathophysiology of NASH in endocrine diseases.

Karim Gariani1, François R Jornayvaz1,2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world. NAFLD encompasses a whole spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. The latter can lead to hepatocellular carcinoma. Furthermore, NASH is the most rapidly increasing indication for liver transplantation in western countries and therefore represents a global health issue. The pathophysiology of NASH is complex and includes multiple parallel hits. NASH is notably characterized by steatosis as well as evidence of hepatocyte injury and inflammation, with or without fibrosis. NASH is frequently associated with type 2 diabetes and conditions associated with insulin resistance. Moreover, NASH may also be found in many other endocrine diseases such as polycystic ovary syndrome, hypothyroidism, male hypogonadism, growth hormone deficiency or glucocorticoid excess, for example. In this review, we will discuss the pathophysiology of NASH associated with different endocrinopathies.

Entities:  

Keywords:  NAFLD; NASH; endocrine diseases; insulin resistance

Year:  2021        PMID: 33449917     DOI: 10.1530/EC-20-0490

Source DB:  PubMed          Journal:  Endocr Connect        ISSN: 2049-3614            Impact factor:   3.335


  11 in total

Review 1.  Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.

Authors:  Sandra Torres; Paula Segalés; Carmen García-Ruiz; José C Fernández-Checa
Journal:  Cells       Date:  2022-04-27       Impact factor: 7.666

Review 2.  Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.

Authors:  Marija Branković; Igor Jovanović; Marija Dukić; Tijana Radonjić; Svetlana Oprić; Slobodan Klašnja; Marija Zdravković
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

3.  Serum 25(OH)D Levels Modify the Association between Triglyceride and IR: A Cross-Sectional Study.

Authors:  Rongpeng Gong; Xin Tang; Ziying Jiang; Gang Luo; Chaofan Dong; Xiuxia Han
Journal:  Int J Endocrinol       Date:  2022-05-10       Impact factor: 2.803

4.  Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Yan-Min Chen; Chun-Fang Lian; Qian-Wen Sun; Ting-Ting Wang; Yuan-Yuan Liu; Jun Ye; Li-Li Gao; Yan-Fang Yang; Shuai-Nan Liu; Zhu-Fang Shen; Yu-Ling Liu
Journal:  Antioxidants (Basel)       Date:  2022-05-05

Review 5.  Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.

Authors:  João Paulo Margiotti Dos Santos; Mariana Canevari de Maio; Monike Alves Lemes; Lucas Fornari Laurindo; Jesselina Francisco Dos Santos Haber; Marcelo Dib Bechara; Pedro Sidnei do Prado; Eduardo Costa Rauen; Fernando Costa; Barbara Cristina de Abreu Pereira; Uri Adrian Prync Flato; Ricardo de Alvares Goulart; Eduardo Federighi Baisi Chagas; Sandra Maria Barbalho
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

Review 6.  Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.

Authors:  Maria Mavromati; François R Jornayvaz
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

Review 7.  The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications.

Authors:  Rossella Palma; Annamaria Pronio; Mario Romeo; Flavia Scognamiglio; Lorenzo Ventriglia; Vittorio Maria Ormando; Antonietta Lamazza; Stefano Pontone; Alessandro Federico; Marcello Dallio
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

8.  NAFLD: From Mechanisms to Therapeutic Approaches.

Authors:  Karim Gariani; François R Jornayvaz
Journal:  Biomedicines       Date:  2022-07-20

9.  Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.

Authors:  Qingfu Zhu; Hengrui Li; Zheng Ao; Hao Xu; Jiaxin Luo; Connor Kaurich; Rui Yang; Pei-Wu Zhu; Sui-Dan Chen; Xiao-Dong Wang; Liang-Jie Tang; Gang Li; Ou-Yang Huang; Ming-Hua Zheng; Hui-Ping Li; Fei Liu
Journal:  J Nanobiotechnology       Date:  2022-07-27       Impact factor: 9.429

Review 10.  Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know.

Authors:  Viktoriya Bikeyeva; Ahmed Abdullah; Aleksandra Radivojevic; Anas A Abu Jad; Anvesh Ravanavena; Chetna Ravindra; Emmanuelar O Igweonu-Nwakile; Safina Ali; Salomi Paul; Shreyas Yakkali; Sneha Teresa Selvin; Sonu Thomas; Pousette Hamid
Journal:  Cureus       Date:  2022-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.